Balyasny Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Balyasny Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.63M	Sell	75,000 -75,000	-50%	-$1.45M	﹤0.01%	1874
2025 Q4	$3.23M	Sell	150,000 -233,000	-61%	-$4.91M	﹤0.01%	1629
2025 Q3	$7.38M	Buy	383,000 +93,000	+32%	+$1.66M	0.01%	1198
2025 Q2	$4.96M	Buy	+290,000	New	+$12.4M	0.01%	1299
2024 Q1	–	Sell	-43,800	Closed	-$4.22M	–	3094
2023 Q4	$4.22M	Sell	43,800 -91,600	-68%	-$8.79M	0.01%	1179
2023 Q3	$16.4M	Hold	135,400	–	–	0.03%	651
2023 Q2	$15.5M	Sell	135,400 -110,000	-45%	-$14.2M	0.03%	616
2023 Q1	$33.8M	Sell	245,400 -163,700	-40%	-$21.2M	0.08%	334
2022 Q4	$53M	Buy	409,100 +29,500	+8%	+$3.42M	0.15%	178
2022 Q3	$42M	Buy	379,600 +100,800	+36%	+$10.2M	0.13%	191
2022 Q2	$20.9M	Buy	278,800 +112,700	+68%	+$8.29M	0.07%	410
2022 Q1	$13M	Buy	166,100 +122,100	+278%	+$9.35M	0.04%	592
2021 Q4	$3.96M	Sell	44,000 -18,000	-29%	-$1.54M	0.01%	921
2021 Q3	$5.73M	Buy	+62,000	New	+$4.78M	0.02%	772

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Balyasny Asset Management's SRPT Position: Q1 2026 in Review

Balyasny Asset Management increased its Sarepta Therapeutics (SRPT) stake by 328% in Q1 2026, buying an estimated $5.81M and bringing the position to 392,044 shares worth $8.53M. The position accounts for 0.01% of the portfolio, ranked #1107.

Balyasny Asset Management first reported a position in SRPT in Q2 2013 and has held it in 33 quarters since. The position peaked at $84.2M in Q2 2024. 340 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

Balyasny Asset Management held 392,044 shares of Sarepta Therapeutics worth $8.53M as of Q1 2026.
Balyasny Asset Management bought 300,425 Sarepta Therapeutics shares in Q1 2026, an estimated $5.81M.
Sarepta Therapeutics made up 0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1107 holding.
Balyasny Asset Management first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 33 quarters since.
Balyasny Asset Management's Sarepta Therapeutics position peaked at $84.2M in Q2 2024.
340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.